PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

eyeforpharma’s latest whitepaper shows why GSK’s ‘New Commercial Model’ is bringing results

11/16/2016 by Jennifer Hagemann

PRESS RELEASE

Putting resources behind the rhetoric of customer-centricity can pay dividends, as eyeforpharma’s new whitepaper documents in its exploration of the impact of GSK’s ‘New Commercial Model’.

While customer-centricity is a buzzword, structuring change around this objective is still consider controversial. That’s why GSK’s new ‘Ethics-first’ approach to commercialization, which includes the decoupling of incentives from sales performance and the suspension of payments to KOLs, was initially received with a dose of skeptism by industry commentators. But the results speak for themselves, with a 2015 survey of more than 3,500 HCPs in the United States ranking GSK number one by trust and customer value.

The pathway to change was not straightforward however, and eyeforpharma’s whitepaper traces this story for the first time, containing valuable insights learned from the obstacles overcome along the way.

Speaking to the publication of this new paper John LaMattina (former president of Pfizer R&D and thought-leader on ethics within pharma), stated “Several lessons can be learnt from the GSK model, including the needs for a middle ground between results-oriented and customer-oriented performance metrics, using meaningful feedback to improve sales rep performance, and transforming selling into a ‘meaningful’ purpose.” By shining a spotlight on this landmark advancement, eyeforpharma aims to evangelize customer-centricity values, encouraging other companies to adopt ideas that can make the industry a better partner in healthcare.

The paper was created from a deep research process involving an extensive literature review of best practices, as well as 8 thought leader interviews with industry experts and GSK colleagues who worked closely with the project. You can read the paper here https://1.eyeforpharma.com/LP=15268
For more cutting-edge thought-leadership from eyeforpharma on the future of commercial models checkout www.eyeforpharma.com

For more information, contact:
Izzy Gladstone, Marketing Director, North America
E: [email protected] T: +44 (0) 207 375 7519 M: 347 458 1621

Filed Under: Features, Industry News, Marketing Channel Posts, Pharma Channel Posts

  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.

Upcoming Events

  1. 6th CAR-TCR Summit Europe

    February 21 - February 23
  2. 7th Virtual Clinical Trials Summit

    May 16 - May 17

View All Events

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2023 PharmaLeaders.com. All rights reserved.